Pharmacokinetics of intravenously administered digoxin and histopathological picture in rabbits with experimental bile duct obstruction

European Journal of Pharmaceutical Sciences

Volumn 11, Issue 3, 2000, Pages 215-222

  Wójcicki, Maciej ^a   Droździk, Marek ^a   Sulikowski, Tadeusz ^a   Wójcicki, Jerzy ^a   Gawrońska Szklarz, Barbara ^a   Zieliński, Staniław ^a   Rózewicka, Lidia ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Cholestasis; Digoxin; Pharmacokinetics

Indexed keywords

DIGOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; JAUNDICE; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RABBIT;

ANIMALS; AREA UNDER CURVE; CHOLESTASIS; DIGOXIN; HALF-LIFE; INJECTIONS, INTRAVENOUS; KIDNEY; LIVER; MALE; METABOLIC CLEARANCE RATE; RABBITS;

EID: 0343962709     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00096-8     Document Type: Article

References (32)

1. Aronson D.C., Chamuleau R., Frederiks W.M., Gooszen H.G., Heijmans H., James J. Reversibility of cholestatic changes following common bile duct obstruction: Fact or fantasy? J. Hepatol. 18:1993;85-95.
2. Basseches P.J., Digregorio G.J. Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. J. Pharmaceut. Sci. 71:1982;1256-1259.
3. Ben-Itzhak J., Bassan H.M., Shor R., Lanir A. Digoxin quinidine interaction: a pharmacokinetic study in the isolated perfused rat liver. Life Sci. 37:1985;411-415.
4. Beveridge T., Nuesch E., Ohnhaus E.E. Absolute bioavailability of digoxin tablets. Arzneimittelforsch. 28:1978;701-703.
5. Blamey S.L., Fearon K.C., Gilmour W.H., Osborne D.H., Carter D. Prediction of risk in biliary surgery. Br. J. Surg. 70:1983;535-538.
6. Caldwell J.H., Cline C.T. Biliary excretion of digoxin in man. Clin. Pharmacol. Ther. 19:1976;410-415.
7. Carulli N., Maneti E., de Leon P. Alteration of drug metabolism during cholestasis in man. Eur. J. Clin. Invest. 5:1975;455-462.
8. Dibona G.F., Sawin L.L. Role of renal nerves in sodium retention in cirrhosis and congestive heart failure. Am. J. Physiol. 260:1991;R298-R305.
9. Doherty M.D., Perkins W.H., Mitchel G.K. Tritiated digoxin studies in human subjects. Arch. Intern. Med. 108:1961;531-536.
10. Elfstrom J., Lindgren S. Disappearance of phenazone from plasma in patients with obstructive jaundice. Eur. J. Pharmacol. 7:1974;467-471.
11. Epstein M. Renal eikosanoids as determinants of renal function in liver disease. Hepatology. 7:1987;1359-1367.
12. Epstein M., Norisk P. Epstein M. The Kidney in Liver Disease. 3rd Edition :1983;331 Williams and Wilhins, Baltimore.
13. Fruncillo R.J., Deangelis P., Digregore J. Pharmacokinetics of theophylline in rats with biliary stasis. J. Pharm. Pharmacol. 34:1982;741.
14. Gawrońska-Szklarz B., Wójcicki J., Kardel-Mizerska T., Kustroń B. Influence of biliary stasis and surgical procedure on the pharmacokinetics of tetracycline given intragastrically (in Polish). Pol. Przegl. Chir. 35:1983;543-549.
15. Harrison L.I., Gibaldi M. Pharmacokinetics of digoxin in the rat. Drug Metab. Res. 4:1976;88-93.
16. Haustein K.O. Interindividual differences in the pharmacokinetics of digoxin and digitoxin during long-term treatment. Eur. J. Clin. Pharmacol. 19:1981;45-51.
17. Hepner G.W., Vesell E.S. Normal antipyrine metabolism in patients with cholesterol cholelithiasis evidence that the disease is not due to generalized hepatic microsomal dysfunction. Am. J. Digest. Dis. 20:1975;9-12.
18. Ichikawa I., Brenner B.M. Glomerular actions of angiotensin II. Am. J. Med. 76:1984;43-49.
19. Kramer W.G., Reuning R.H. Use of area under the curve to estimate absolute bioavailability of digoxin. J. Pharm. Sci. 64:1978;141-142.
20. McLuen E.F., Fouts J.R. The effect of obstructive jaundice on drug metabolism in rabbits. J. Pharmacol. Exp. Ther. 131:1961;7-12.
21. Miyazawa Y., Sato T., Kobayashi K., Akahori F., Suzuki T., Miyashita H. Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs. Am. J. Vet. Res. 51:1990;605-610.
22. Moore K., Wendon J., Frazer M., Karani J., Williams R., Badr K. Plasma endothelium immunoreactivity in liver disease and the hepatorenal syndrome. New Engl. J. Med. 327:1992;1774-1778.
23. Moore K. The hepatorenal syndrome. Clin. Sci. 92:1997;433-443.
24. Ochs H., Bodem G., Bales G., Greenblatt D., Smith T. Increased clearance of digoxin in rabbits during repeated administration. J. Pharmacol. Exp. Ther. 204:1978;262-270.
25. Orlando R., Floreani M., Padrini R., Palatini P. Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis. Clin. Nephrol. 51:1999;341-347.
26. Ozawa K., Yamada T., Tanaka J., Ukiksua M., Tobe T. The mechanism of suppression of renal function in patients and rabbits in jaundice. Surg. Gynecol. Obstet. 149:1979;54-60.
27. Peters U., Falk L.C., Kakman S.H. Digoxin metabolism in patients. Arch. Intern. Med. 138:1978;1074-1076.
28. Romeis B. Mikroskopische Technik. 1968;59 R. Oldenbourg Verlag, Muchen-Vien.
29. Sitprija V., Kashemsant U., Sriratanban A., Arthachinta S., Poshyachinda V. Renal function in obstructive jaundice in man: cholangiocarcinoma model. Kidney Int. 38:1990;948-955.
30. Tateishi T., Watanabe M., Nakura H., Tanaka M., Kumai T., Kobayashi S. Liver damage induced by bile duct ligation affects CYP isoenzymes differently in rats. Pharm. Toxocol. 82:1998;89-92.
31. Weidler D.J., Jallad N.S., Movahhed H.S., Sakmar E., Wagner J.G. Pharmacokinetics of digoxin in the cat and comparisons with man and the dog. Res. Commun. Chem. Pathol. Pharmacol. 19:1978;57-66.
32. Zambraski E.J., Dibona G.F. Epstein M. The Kidney in Liver Disease. 3rd Edition :1983;469 Williams and Wilkins, Baltimore.